Metformin

Minimize Acute COVID-19 Symptoms

Metformin offers antiviral properties that help reduce the severity of acute COVID-19 symptoms, lowering viral loads and minimizing complications.

Inflammation Reduction

Metformin exhibits anti-inflammatory effects, potentially mitigating systemic inflammation characteristic of acute COVID-19 and Long COVID.

Reduced Risk of Long COVID

Research shows that metformin reduces the risk of Long COVID by up to 53% when taken within the first week of infection.

Study #1: Minimize Acute COVID-19 Symptoms

Metformin demonstrated antiviral properties in a study where participants treated with metformin during acute COVID-19 experienced a fourfold reduction in viral load compared to the placebo group.

Metformin and Antiviral Effects in Acute COVID-19

Study #2: Inflammation Reduction

Metformin exhibits anti-inflammatory properties that may mitigate systemic inflammation present in acute COVID-19 and Long COVID. These effects could reduce the severity of acute infections and the risk of Long COVID development.

Metformin May Reduce Long COVID in Non-Diabetic Population

Study #3: Reduced Risk of Long COVID

Data presented at the 2024 Infectious Disease Week Annual Meeting revealed that metformin reduced the risk of Long COVID by 53% when prescribed within the first week of an acute SARS-CoV-2 infection.

Metformin for Long COVID Prevention and Unveiling the potential pleiotropic effects of metformin in treating COVID-19: a comprehensive review